GlassScriptPhysician profile
Joel S Cohen
NPI 1700874518
$5,085.66
in general payments reported to CMS, 2019-2025
28 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $445 · 2021: $616 · 2022: $1,120 · 2023: $739 · 2024: $771 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,177.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.56 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $783.87 | 2019-2021 | |
| Notal Vision, INC. | $378.82 | 2022 | |
| Bausch & Lomb Americas INC. | $370.55 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $301.15 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.39 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $248.56 | 2019-2021 | |
| Horizon Therapeutics Plc | $230.78 | 2020-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $180.11 | 2019-2021 | |
| Thea Pharma INC. | $179.49 | 2022-2025 | Iyuzeh |
| Alcon Vision LLC | $178.38 | 2022-2025 | Tryptyr, Rocklatan, Clareon |
| Shire North American Group INC | $161.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $150.47 | 2019-2023 | |
| Genentech USA, INC. | $140.46 | 2022-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2024 | Eylea Hd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $89.10 | 2022-2023 | Oxervate |
| Biogen, INC. | $65.01 | 2022-2024 | Byooviz |
| Astellas Pharma US INC | $48.55 | 2024-2025 | Izervay |
| Sight Sciences, INC. | $45.95 | 2022-2025 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $42.93 | 2020-2022 | |
| Akorn Operating Company LLC | $41.61 | 2021 | |
| Biotissue Holdings INC. | $40.09 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $38.97 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $34.58 | 2022 | |
| Harrow Eye, LLC | $28.15 | 2025 | Vevye |
| Amgen INC. | $18.58 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $16.08 | 2023 | Syfovre |
| Rxsight INC | $15.73 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.